Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma.
The platelet-to-lymphocyte ratio (PLR) is reported to be a prognostic factor in multiple malignancies. The aim of this study was to assess its prognostic value in hepatocellular carcinoma (HCC). We performed comprehensive searches of electronic databases for relevant studies. A total of eleven studies comprising 2,507 patients were included. Elevated PLR was significantly associated with poor overall survival (OS) (HR = 1.78; 95% CI = 1.36-2.34; P < 0.001) and disease-free survival (DFS)/recurrence-free survival (RFS) (HR = 1.82; 95% CI = 1.56-2.13; P < 0.001). The findings from most subgroup analyses were consistent with those from the overall analysis. In addition, a high PLR correlated with tumor size > 3 cm, TNM stage, lymph node metastasis, distant metastasis, and vascular invasion. We therefore conclude that elevated pretreatment PLR may be predicative of a poor prognosis in patients with HCC.
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Wei
W
Song
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Kai
K
Wang
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Fu-Ping
FP
Zhong
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
You-Wen
YW
Fan
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Lang
L
Peng
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Shu-Bing
SB
Zou
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D016009:Chi-Square Distribution; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D008207:Lymphatic Metastasis; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016017:Odds Ratio; D010976:Platelet Count; D011237:Predictive Value of Tests; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D055815:Young Adult
biomarker; hepatocellular carcinoma; meta-analysis; platelet to lymphocyte ratio (PLR); prognosis